|
|
|
Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC
|
|
Vanita Pindolia, PharmD, MBA
Vice President
Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System (HFHS)
Health Alliance Plans (HAP)
|
|
A. Krishna Rao, MD, MS
Assistant Professor
Division of Infectious Diseases
Department of Internal Medicine
University of Michigan Medical School
|
|
TARGET AUDIENCE
|
- Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, nurses, care managers, and other managed care and payer organization professionals
|
|
PROGRAM OVERVIEW
|
The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.
A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations. In addition, the faculty panel, including managed care experts, will review guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.
|
|
EDUCATIONAL OBJECTIVES
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Review the epidemiology and prevalence of C. Difficile Infection (CDI)
- Evaluate novel treatment options for primary and recurrent CDI
- Apply guideline-based management strategies for CDI
- Illustrate avoidable costs related to CDI treatment management that can impact benefit design and coverage decision-making
|
|
AGENDA
|
|
12:00 PM
|
Opening Comments/Overview
Vanita Pindolia, PharmD, BCPS, MBA
|
|
12:05 PM
|
CDI Clinical Update – Why the Increase?
A. Krishna Rao, MD, MS
|
|
12:35 PM
|
Care Management Strategies to Address the Rising Costs of CDI
Edmund Pezalla, MD, MPH
|
|
12:55 PM
|
CDI Case Scenarios and Best Practice Recommendations
Vanita Pindolia, PharmD, BCPS, MBA
|
|
1:15 PM
|
Audience Q&A Session
Key Takeaways and Closing Comments
|
|
1:30 PM
|
Adjournment
|
ACCREDITATION INFORMATION
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Credit
 |
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0816-9999-20-140-L01-P
This activity is certified as Knowledge-based CPE.
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Faculty |
Reported Financial Relationships |
| Edmund Pezalla, MD, MPH |
TBD |
| Vanita Pindolia, PharmD, BCPS, MBA |
TBD |
| A. Krishna Rao, MD, MS |
Grants/Research Support: Merck & Co., Inc.
Consulting Fees (eg. Ad boards): Bio-K+ International, Inc. |
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Content Manager |
Reported Financial Relationships |
| Impact Education, LLC. Content Managers |
No financial interest/relationships relating to the topic of this activity |
| MER Content Managers |
No financial interest/relationships relating to the topic of this activity |
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
There is no fee for this educational activity.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
| | | | |
